Your Search Returned 24 tagged news reports
The largest US-based pharmaceutical beat earnings estimates but revenues fell well short of consensus estimate, and declined on a year-over-year (YoY) basis...The company reported revenues of $11.3 billion during the quarter, missing the Street's
Teva Pharmaceutical Industries Ltd., Actavis Plc and Lupin Ltd. are among the generic-drug makers that would infringe a valid patent on the pain medicine, the U.S. Court of Appeals for the Federal Circuit in Washington said in an opinion today on its
has left investors anything but disappointed this year, as the blue-chip index has gained more than 22% year to date. PFE ) been one of the Dow's better surprises in 2013, outpacing the index's gains with a year-to-date jump of more than 27%.
Apart from meeting the primary endpoint, the fibromyalgia study of Lyrica in the treatment of FM pain showed reduction in pain in patients who were treated concurrently with antidepressant therapy for comorbid depression. Additionally, the company
Perhaps nothing defines today's pharmaceutical industry as accurately as the "patent cliff." The expiration of the patents of numerous high-selling, high-profile drugs has dominated the industry like no other topic in 2012...The company's best-
It has been almost two months since we lasted noted misbehavior by giant global pharmaceutical firm Pfizer Inc. With little fanfare, however, a few small news items noted the corporation's latest legal settlements. Deceptive Marketing of Protonix The
Alabama and 32 other states and the District of Columbia will share a $42.9 million settlement reached with Pfizer, Inc. as part of a lawsuit arguing the company violated deceptive trade practices laws, according to court documents filed today.
A view of the Belgian headquarters of U.S. pharmaceutical giant Pfizer, in Brussels in this January 23, 2007 file photo. PFE ) trading around $24.53, is PFE a Buy, a Wait and See, or a Stay Away?...The biggest selling point is that Lyrica only needs
reported this morning that advanced studies of a drug treating fibromyalgia performed better than placebos, bringing the drug a step closer to being declared effective in once-a-day doses. According to the press release, fibromyalgia affects more
today announced top-line results of a double-blind, placebo-controlled, Phase 3 study evaluating both the 165 mg dose and the 330 mg dose of pregabalin controlled-release (CR) formulation in adult patients with partial onset seizures with epilepsy.